CA1168583A - Preparation favorisant la coagulation du sang a base de proteines humaines et methode de production - Google Patents

Preparation favorisant la coagulation du sang a base de proteines humaines et methode de production

Info

Publication number: CA1168583A
Authority: CA; Canada
Prior art keywords: activity; preparation; protein; factor; feib
Prior art date: 1980-07-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000382131A

Other languages

English (en)

Inventor

Johann Eibl

Otto Schwarz

Fritz Elsinger

Anton Philapitsch

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Oesterreichisches Institut fuer Haemoderivate

Original Assignee

Immuno AG fuer Chemisch Medizinische Produkte

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-07-22

Filing date

1981-07-21

Publication date

1984-06-05

1981-01-08 Priority claimed from AT3781A external-priority patent/AT376966B/de

1981-07-21 Application filed by Immuno AG fuer Chemisch Medizinische Produkte filed Critical Immuno AG fuer Chemisch Medizinische Produkte

1984-06-05 Application granted granted Critical

1984-06-05 Publication of CA1168583A publication Critical patent/CA1168583A/fr

Status Expired legal-status Critical Current

Links

238000002360 preparation method Methods 0.000 title claims abstract description 90
238000000034 method Methods 0.000 title claims abstract description 40
102000003839 Human Proteins Human genes 0.000 title claims abstract description 13
108090000144 Human Proteins Proteins 0.000 title claims abstract description 13
230000000694 effects Effects 0.000 claims abstract description 98
102000004169 proteins and genes Human genes 0.000 claims abstract description 77
108090000623 proteins and genes Proteins 0.000 claims abstract description 77
108010018823 anti-inhibitor coagulant complex Proteins 0.000 claims abstract description 54
229940105776 factor viii inhibitor bypassing activity Drugs 0.000 claims abstract description 54
239000000203 mixture Substances 0.000 claims abstract description 35
102000015081 Blood Coagulation Factors Human genes 0.000 claims abstract description 12
108010039209 Blood Coagulation Factors Proteins 0.000 claims abstract description 12
239000003114 blood coagulation factor Substances 0.000 claims abstract description 12
235000014633 carbohydrates Nutrition 0.000 claims abstract description 12
150000001720 carbohydrates Chemical class 0.000 claims abstract description 12
238000010828 elution Methods 0.000 claims abstract description 12
229920000642 polymer Polymers 0.000 claims abstract description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 70
102100022641 Coagulation factor IX Human genes 0.000 claims description 37
108010076282 Factor IX Proteins 0.000 claims description 37
229960004222 factor ix Drugs 0.000 claims description 37
239000011780 sodium chloride Substances 0.000 claims description 33
238000011534 incubation Methods 0.000 claims description 20
229920002307 Dextran Polymers 0.000 claims description 19
108060005987 Kallikrein Proteins 0.000 claims description 17
102000001399 Kallikrein Human genes 0.000 claims description 17
150000002500 ions Chemical class 0.000 claims description 17
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 15
229910021653 sulphate ion Inorganic materials 0.000 claims description 15
108010071241 Factor XIIa Proteins 0.000 claims description 14
208000007536 Thrombosis Diseases 0.000 claims description 12
108010093564 inter-alpha-inhibitor Proteins 0.000 claims description 12
230000002885 thrombogenetic effect Effects 0.000 claims description 11
241000283973 Oryctolagus cuniculus Species 0.000 claims description 10
238000000926 separation method Methods 0.000 claims description 10
239000000126 substance Substances 0.000 claims description 10
229920000936 Agarose Polymers 0.000 claims description 9
230000002950 deficient Effects 0.000 claims description 9
230000001939 inductive effect Effects 0.000 claims description 8
229940124135 Factor VIII inhibitor Drugs 0.000 claims description 7
239000007864 aqueous solution Substances 0.000 claims description 7
238000005345 coagulation Methods 0.000 claims description 3
230000015271 coagulation Effects 0.000 claims description 3
108091006629 SLC13A2 Proteins 0.000 claims 1
239000000523 sample Substances 0.000 description 22
238000010790 dilution Methods 0.000 description 17
239000012895 dilution Substances 0.000 description 17
239000000243 solution Substances 0.000 description 16
229920005654 Sephadex Polymers 0.000 description 13
239000012507 Sephadex™ Substances 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
239000012528 membrane Substances 0.000 description 8
239000003153 chemical reaction reagent Substances 0.000 description 7
210000004379 membrane Anatomy 0.000 description 7
239000001509 sodium citrate Substances 0.000 description 7
TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 6
239000003593 chromogenic compound Substances 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
229920001817 Agar Polymers 0.000 description 5
239000005995 Aluminium silicate Substances 0.000 description 5
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
239000008272 agar Substances 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000001110 calcium chloride Substances 0.000 description 5
229910001628 calcium chloride Inorganic materials 0.000 description 5
238000001914 filtration Methods 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
108090000113 Plasma Kallikrein Proteins 0.000 description 4
229920002684 Sepharose Polymers 0.000 description 4
235000012211 aluminium silicate Nutrition 0.000 description 4
238000011088 calibration curve Methods 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 4
235000019263 trisodium citrate Nutrition 0.000 description 4
229940038773 trisodium citrate Drugs 0.000 description 4
210000003462 vein Anatomy 0.000 description 4
102000009027 Albumins Human genes 0.000 description 3
108010088751 Albumins Proteins 0.000 description 3
108010048049 Factor IXa Proteins 0.000 description 3
108010094028 Prothrombin Proteins 0.000 description 3
102100027378 Prothrombin Human genes 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
238000013375 chromatographic separation Methods 0.000 description 3
230000035602 clotting Effects 0.000 description 3
230000005684 electric field Effects 0.000 description 3
229940067631 phospholipid Drugs 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
229940039716 prothrombin Drugs 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
229960001790 sodium citrate Drugs 0.000 description 3
235000011083 sodium citrates Nutrition 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000011282 treatment Methods 0.000 description 3
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000013590 bulk material Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
239000012847 fine chemical Substances 0.000 description 2
108010074605 gamma-Globulins Proteins 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000004033 plastic Substances 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
239000013026 undiluted sample Substances 0.000 description 2
230000002227 vasoactive effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
ZAMLGGRVTAXBHI-UHFFFAOYSA-N 3-(4-bromophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(CC(O)=O)C1=CC=C(Br)C=C1 ZAMLGGRVTAXBHI-UHFFFAOYSA-N 0.000 description 1
102000004411 Antithrombin III Human genes 0.000 description 1
108090000935 Antithrombin III Proteins 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
108010014172 Factor V Proteins 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
201000003542 Factor VIII deficiency Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
229920001499 Heparinoid Polymers 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
229940081735 acetylcellulose Drugs 0.000 description 1
239000013543 active substance Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
229960005348 antithrombin iii Drugs 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000004043 dyeing Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
238000011049 filling Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
208000009429 hemophilia B Diseases 0.000 description 1
239000002554 heparinoid Substances 0.000 description 1
229940025770 heparinoids Drugs 0.000 description 1
229920006158 high molecular weight polymer Polymers 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
238000002690 local anesthesia Methods 0.000 description 1
238000012792 lyophilization process Methods 0.000 description 1
229940105631 nembutal Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000000376 reactant Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229960001866 silicon dioxide Drugs 0.000 description 1
239000007858 starting material Substances 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

CA000382131A 1980-07-22 1981-07-21 Preparation favorisant la coagulation du sang a base de proteines humaines et methode de production Expired CA1168583A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AT3781/80		1980-07-22
AT3781A AT376966B (de)	1980-01-08	1981-01-08	Verfahren zur herstellung eines furanderivats

Publications (1)

Publication Number	Publication Date
CA1168583A true CA1168583A (fr)	1984-06-05

Family

ID=3479855

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000382131A Expired CA1168583A (fr)	1980-07-22	1981-07-21	Preparation favorisant la coagulation du sang a base de proteines humaines et methode de production

Country Status (2)

Country	Link
JP (1)	JPS5928536B2 (fr)
CA (1)	CA1168583A (fr)

1981
- 1981-07-21 CA CA000382131A patent/CA1168583A/fr not_active Expired
- 1981-07-21 JP JP56115015A patent/JPS5928536B2/ja not_active Expired

Also Published As

Publication number	Publication date
JPS5753408A (en)	1982-03-30
JPS5928536B2 (ja)	1984-07-13

Legal Events

Date	Code	Title	Description
2001-06-05	MKEX	Expiry

Publication	Publication Date	Title
US4395396A (en)	1983-07-26	Blood-coagulation-promoting preparation based on human proteins and a method of producing the same
Brash et al.	1984	Effect of plasma dilution on adsorption of fibrinogen to solid surfaces
Read et al.	1978	Venom coagglutinin: an activator of platelet aggregation dependent on von Willebrand factor.
Gralnick et al.	1975	Studies of the human factor VIII/von Willebrand factor protein. III. Qualitative defects in von Willebrand's disease.
Chuang et al.	1978	Interaction of plasma proteins with artificial surfaces: protein adsorption isotherms
FI57421C (fi)	1980-08-11	Foerfarande foer framstaellning av ett preparat ur maenniskoblodplasma med blodets koagulation befraemjande verkan
Heystek et al.	1973	Contributions to the optimal use of human blood
US3717708A (en)	1973-02-20	Blood coagulation complex
EP0482088A1 (fr)	1992-04-29	Regulations ameliorees pour effectuer une coagulation stable du sang
US4364861A (en)	1982-12-21	Blood-coagulation-promoting products and methods of preparing them
Lind et al.	1984	Human plasma gelsolin binds to fibronectin.
Firkin et al.	1978	Demonstration of a platelet bypass mechanism in the clotting system using an acquired anticoagulant
DK169439B1 (da)	1994-10-31	Anvendelse af monospecifikke anti-L1-antisera og monospecifikke anti-L1-antistoffer til kvalitativ eller kvantitativ bestemmeles af L1-proteiner i celler, væv eller legemsvæsker, samt testudstyr med indhold deraf
Harpel	1971	Separation of plasma thromboplastin antecedent from kallikrein by the plasma α 2-macroglobulin, kallikrein inhibitor
Chaplin et al.	1986	Acute intravascular hemolytic anemia in the black rhinoceros: hematologic and immunohematologic observations
US4361510A (en)	1982-11-30	Blood coagulation promoting product
Gralnick et al.	1987	A variant of type II von Willebrand disease with an abnormal triplet structure and discordant effects of protease inhibitors on plasma and platelet von Willebrand factor structure
Wickerhauser et al.	1972	Development of Large-Scale Fractionation Methods
Brocklehurst et al.	1966	The purification of a kininogen from human plasma
Furlong et al.	1983	An electroblotting technique for the detection of factor VIII/von Willebrand factor multimers in plasma
Rubio et al.	1983	Prothrombin Habana: a new dysfunctional molecule of human prothrombin associated with a true prothrombin deficiency
EP0041174B1 (fr)	1985-09-11	Produit activant la coagulation du sang et procédé pour sa préparation
Cooper et al.	1974	The cold-insoluble globulin of plasma and its relationship to factor VIII
EP0239644A1 (fr)	1987-10-07	Nouvelle substance physiologiquement active limitant la coagulation du sang
US4391746A (en)	1983-07-05	Blood-coagulation-promoting products and methods of preparing them